This article shows how the FTC is investigating the large PBM Rebate Walls. They are bringing to light that the dominant PBMs often co-opt big pharma’s strategic rebates (PBM Rebate Walls), designed to make competitive entry more difficult. Making it almost impossible, for generic alternatives to compete in the market. Large PBMs then reap the resulting benefits for themselves, as opposed to passing them on to their customers, the plan sponsors. If there is anything on this topic you would like to discuss, please reach out to us here at BenefitHelp by email [firstname.lastname@example.org].
Here is a link to the article on BenefitsPro’s website: